Company news
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) news
Rhythm Pharmaceuticals, Inc. news releases on 6ix. Latest, May 3, 2022: Rhythm Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Update
Press releases — page 4
Rhythm Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Update
May 2, 2022
Rhythm Pharmaceuticals Presents New Data from Phase 3 Trial Evaluating Setmelanotide in Patients with Bardet-Biedl Syndrome (BBS) at the Pediatric Endocrine Society (PES) 2022 Virtual Annual Meeting
May 1, 2022
Rhythm Pharmaceuticals to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022
April 25, 2022
Rhythm Pharmaceuticals Optimizes Design of EMANATE and DAYBREAK Clinical Trials to Advance Setmelanotide for Rare Genetic Diseases of Obesity
April 5, 2022
Rhythm Pharmaceuticals to Present at Cowen & Co. 42nd Annual Health Care Conference
February 28, 2022
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
February 28, 2022
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome
February 23, 2022
Rhythm Pharmaceuticals Announces Promotions within its Executive Leadership Team
February 22, 2022
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on Tuesday, March 1, 2022
February 21, 2022
Rhythm Pharmaceuticals Announces Positive Interim Data from Long-term Extension Study of Setmelanotide in Bardet-Biedl Syndrome (BBS)
February 15, 2022
Rhythm Pharmaceuticals to Host Virtual Bardet-Biedl Syndrome (BBS) Event on February 16
February 7, 2022
Rhythm Pharmaceuticals Announces First Patients Dosed in DAYBREAK and Weekly Trials Evaluating Setmelanotide for Rare Genetic Diseases of Obesity
January 12, 2022
Rhythm Pharmaceuticals and RareStone Ltd. Announce Exclusive Licensing Agreement for the Development and Commercialization of IMCIVREE (setmelanotide) in China
December 5, 2021
Rhythm Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome
November 14, 2021
Rhythm Pharmaceuticals to Present at Stifel 2021 Virtual Healthcare Conference
November 8, 2021
Rhythm Pharmaceuticals Reports Third Quarter 2021 Financial Results
November 1, 2021
Rhythm Pharmaceuticals Presents First-ever Data Showing Improvements in Health-related Quality of Life for Patients Living with Bardet-Biedl Syndrome at ObesityWeek® 2021
October 31, 2021
Rhythm Pharmaceuticals to Report Third Quarter 2021 Financial Results on Tuesday, November 2, 2021
October 19, 2021
Rhythm Pharmaceuticals Presents New Data on Experience of People Living with Rare Genetic Diseases of Obesity and Provides Updates on Uncovering Rare Obesity® Genetic Testing Program
October 13, 2021
Rhythm Pharmaceuticals Completes Submission of Type II Variation Application to the European Medicines Agency for IMCIVREE® (setmelanotide) for Bardet-Biedl and Alström Syndromes
October 13, 2021
Rhythm Pharmaceuticals Presents New Data from Phase 2 and 3 Trials Evaluating Setmelanotide in Multiple Rare Genetic Diseases of Obesity at the 59th Annual ESPE Meeting
September 21, 2021
Rhythm Pharmaceuticals Announces Marketing Authorisation of IMCIVREE® (setmelanotide) in Great Britain
September 20, 2021
CORRECTION: Rhythm Pharmaceuticals, Inc.
September 20, 2021
Rhythm Pharmaceuticals Completes Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for IMCIVREE® (setmelanotide) for the treatment of obesity and control of hunger in Bardet-Biedl and Alström Syndromes
September 19, 2021
Rhythm Pharmaceuticals Announces Expanded Access Program for Setmelanotide for Patients with Bardet-Biedl Syndrome
September 7, 2021
Rhythm Pharmaceuticals to Present at Morgan Stanley 19th Annual Global Healthcare Conference
September 1, 2021
Rhythm Pharmaceuticals Announces CMO Transition
September 1, 2021
Rhythm Pharmaceuticals to Present at the 59th Annual ESPE Meeting
August 11, 2021
Rhythm Pharmaceuticals to Present at 2021 Canaccord Genuity 41st Annual Growth Conference
August 4, 2021
Rhythm Pharmaceuticals Reports Second Quarter 2021 Financial Results
August 2, 2021
Rhythm Pharmaceuticals Announces Comprehensive Expansion of Clinical Development Program with Five New Phase 2 and 3 Trials Planned to Evaluate Setmelanotide in Rare Genetic Diseases of Obesity
August 2, 2021
Rhythm Pharmaceuticals Announces Senior Leadership Additions
July 28, 2021
Rhythm Pharmaceuticals Announces Collaborative Research Agreement with Clinical Registry Investigating Bardet-Biedl Syndrome
July 27, 2021
Rhythm Pharmaceuticals to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021
July 26, 2021
Rhythm Pharmaceuticals Announces European Commission Authorization of IMCIVREE® (setmelanotide)▼ for the Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR Deficiency
July 22, 2021
Rhythm Pharmaceuticals and Medison Pharma Partner to Commercialize IMCIVREE™ (setmelanotide) in Israel
July 21, 2021
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for Setmelanotide for Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR Deficiency
May 20, 2021
Rhythm Pharmaceuticals Reports First Quarter 2021 Financial Results
May 2, 2021
Rhythm Pharmaceuticals Announces Late-Breaking Data Presentations at ENDO 2021
March 8, 2021
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
February 28, 2021
Rhythm Pharmaceuticals, Inc. Announces Closing of $172.5 Million Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
February 9, 2021
Rhythm Pharmaceuticals Announces Positive Data with Setmelanotide in Additional MC4R Pathway Deficiency-related Obesities
January 25, 2021
Rhythm Pharmaceuticals Announces Sale of Priority Review Voucher for $100M
January 4, 2021
Rhythm Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes
December 21, 2020
Rhythm Pharmaceuticals Announces Appointments of Camille L. Bedrosian, M.D., and Lynn Tetrault, J.D., to its Board of Directors
December 10, 2020
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE™ (setmelanotide) as First-ever Therapy for Chronic Weight Management in Patients with Obesity Due to POMC, PCSK1 or LEPR Deficiency
November 26, 2020
Rhythm Pharmaceuticals Announces New Clinical Data on Setmelanotide at ObesityWeek® 2020
November 3, 2020
Rhythm Pharmaceuticals Reports Third Quarter 2020 Financial Results
November 1, 2020
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trials of Setmelanotide in The Lancet Diabetes & Endocrinology
October 29, 2020
Rhythm Pharmaceuticals Appoints Jennifer Chien as Executive Vice President, Head of North America
October 27, 2020